

Melbourne, 20 November 2017

# Section 708A Cleansing Statement and Appendix 3B

This notice is given by Clean TeQ Holdings Limited (**Company**) under Section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

- (a) the Company has issued 108,471 fully paid ordinary shares (**Shares**) at an issue price of \$0.585 (58.5 cents) in relation to the conversion of unlisted options.
- (b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) section 674 of the Corporations Act as it applies to the Company; and
- (e) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

# For more information about Clean TeQ contact:

Sam Riggall, CEO or Ben Stockdale, CFO +61 3 9797 6700

About Clean TeQ Holdings Limited (ASX:CLQ) – Based in Melbourne, Clean TeQ, using its proprietary Clean-iX® continuous ion exchange technology, is a leader in metals recovery and industrial water treatment.

For more information about Clean TeQ please visit the Company's website <u>www.cleanteq.com</u>.

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

108,471

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

Clean TeQ Holdings Limited

ABN

| 34 | 127 | 457 | 916 |
|----|-----|-----|-----|
|    | /   | 177 | 2   |

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued Fully paid ordinary shares

- 2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- Principal 3 terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares

<sup>+</sup> See chapter 19 for defined terms.

| 4  | Do the *securities rank equally in all<br>respects from the date of allotment<br>with an existing *class of quoted<br>*securities?  | Yes  |
|----|---|--|
|    | <ul> <li>If the additional securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> |  |
|    |   |  |
| 5  | Issue price or consideration  | Nil – issued pursuant to cashless exercise facility in<br>accordance with the approved Employee Incentive<br>Plan Rules. |
| 6  | Purpose of the issue<br>(If issued as consideration for the<br>acquisition of assets, clearly identify<br>those assets  | Conversion of unlisted options exercisable at \$0.585<br>(58.5 cents)  |
| 6a | Is the entity an <sup>+</sup> eligible entity that has<br>obtained security holder approval<br>under rule 7.1A?   | No   |
|    | If Yes, complete sections 6b – 6h <i>in relation to the *securities the subject of this Appendix 3B</i> , and comply with section 6i  |  |
| 6b | The date the security holder resolution under rule 7.1A was passed  | N/A  |
| 6с | Number of *securities issued without security holder approval under rule 7.1  | Nil  |
| 6d | Number of *securities issued with security holder approval under rule 7.1A  | Nil  |
| 6e | Number of <sup>+</sup> securities issued with<br>security holder approval under rule 7.3,<br>or another specific security holder<br>approval (specify date of meeting)  | Nil  |
|    |   |  |

<sup>+</sup> See chapter 19 for defined terms.

- 6f Number of securities issued under an exception in rule 7.2
- 6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.
- 6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 Dates of entering <sup>+</sup>securities into uncertificated holdings or despatch of certificate
- 8 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the securities in section 2 if applicable)
- 9 Number and <sup>+</sup>class of all <sup>+</sup>securities not quoted on ASX (*including* the securities in section 2 if applicable)
- 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

o of consideration ASX Market

N/A

N/A

See Annexure 1

108,471 fully paid ordinary shares

20 November 2017

| Number      | +Class                        |
|-------------|-------------------------------|
| 579,950,182 | Ordinary fully paid<br>shares |
|             |                               |

| 40,467,885 | Options over ordinary shares |
|------------|------------------------------|
| 6,602,183  | Performance Rights           |

| N/A    |  |
|--------|--|
| 1 1/11 |  |
|        |  |
|        |  |
|        |  |

# Part 2 - Bonus issue or pro rata issue

II Is security holder appr required?

| roval N | /A |
|---------|----|
|---------|----|

- 12 Is the issue renounceable or non- N/A renounceable?
- 13 Ratio in which the <sup>+</sup>securities N/A will be offered

N/A

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

| 14 | <sup>+</sup> Class of <sup>+</sup> securities to which the offer relates  | N/A |
|----|---|-----|
| 15 | <sup>+</sup> Record date to determine<br>entitlements   | N/A |
| 16 | Will holdings on different<br>registers (or subregisters) be<br>aggregated for calculating<br>entitlements?   | N/A |
| 17 | Policy for deciding entitlements<br>in relation to fractions  | N/A |
| 18 | Names of countries in which the<br>entity has <sup>+</sup> security holders who<br>will not be sent new issue<br>documents<br>Note: Security holders must be told how their<br>entitlements are to be dealt with.<br>Cross reference: rule 7.7. | N/A |
| 19 | Closing date for receipt of   | N/A |
|    | acceptances or renunciations  |     |
| 20 | Names of any underwriters   | N/A |
| 21 | Amount of any underwriting fee or commission  | N/A |
| 22 | Names of any brokers to the issue   | N/A |
| 23 | Fee or commission payable to the broker to the issue  | N/A |
| 24 | Amount of any handling fee<br>payable to brokers who lodge<br>acceptances or renunciations on<br>behalf of <sup>+</sup> security holders  | N/A |
| 25 | If the issue is contingent on <sup>+</sup> security holders' approval, the date of the meeting  | N/A |

<sup>+</sup> See chapter 19 for defined terms.

| 26 | Date entitlement and acceptance<br>form and prospectus or Product<br>Disclosure Statement will be sent<br>to persons entitled  | N/A |
|----|--|-----|
| 27 | If the entity has issued options,<br>and the terms entitle option<br>holders to participate on<br>exercise, the date on which<br>notices will be sent to option<br>holders | N/A |
| 28 | Date rights trading will begin (if applicable)   | N/A |
| 29 | Date rights trading will end (if applicable)   | N/A |
| 30 | How do <sup>+</sup> security holders sell their entitlements <i>in full</i> through a broker?  | N/A |
| 31 | How do <sup>+</sup> security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?   | N/A |
|    |  |     |
| 32 | How do <sup>+</sup> security holders dispose<br>of their entitlements (except by<br>sale through a broker)?  | N/A |
| 33 | <sup>+</sup> Despatch date   | N/A |
|    |  |     |

<sup>+</sup> See chapter 19 for defined terms.

## Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of securities (*tick one*)
- (a)

Securities described in Part 1

(b) All

All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents


- If the \*securities are \*equity securities, the names of the 20 largest holders of the additional \*securities, and the number and percentage of additional \*securities held by those holders
- 36 If the \*securities are \*equity securities, a distribution schedule of the additional \*securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
- 37

35

A copy of any trust deed for the additional +securities

#### Entities that have ticked box 34(b)

- 38 Number of securities for which <sup>+</sup>quotation is sought
- 39 Class of <sup>+</sup>securities for which quotation is sought



<sup>+</sup> See chapter 19 for defined terms.

Do the <sup>+</sup>securities rank equally in 40 all respects from the date of allotment with an existing <sup>+</sup>class of quoted +securities?

> If the additional securities do not rank equally, please state:

- 1. the date from which they do
- 2. the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they 3. do not rank equally, other than in relation to the dividend, next distribution or interest payment
- 41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

Number and +class of all 42 <sup>+</sup>securities quoted on ASX (including the securities in clause 38)

| Number | +Class |  |
|--------|--------|--|
|        |        |  |
|        |        |  |
|        |        |  |
|        |        |  |
|        |        |  |

| Number | +Class |
|--------|--------|
|        |        |

#### Quotation agreement

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

(Company secretary)

Date: 20 November 2017

Sign here

Print name:

Melanie Leydin

== == == == ==

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for \*eligible entities

Introduced 01/08/12

## Part 1

| Rule 7.1 – Issues exceeding 15% of capital  |  |  |
|---|--|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated  |  |  |
| <i>Insert</i> number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue  | 478,246,636  |  |
| <ul><li><i>Add</i> the following:</li><li>Number of fully paid ordinary securities</li></ul>  | 553,155 - 17 February 2017<br>577,800 – 14 March 2017  |  |
| Number of fully paid ordinary securities  | 135,251 – 23 March 2017<br>92,518,888 – 27 March 2017<br>100,000 – 21 April 2017   |  |
| <ul> <li>shareholder approval</li> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> </ul>  | 600,000 – 5 May 2017<br>288,745 – 5 June 2017<br>3,211,255 – 9 June 2017   |  |
| <ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> | 34,580 – 20 June 2017<br>66,445 – 28 July 2017<br>1,637,001 – 11 August 2017<br>200,751 – 29 August 2017<br>10,219 – 7 September 2017<br>500,000 – 23 October 2017<br>231,884 – 27 October 2017<br>929,101 – 6 November 2017<br>108,471 – 20 November 2017 |  |
| <b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period  | -  |  |
| "A"   | 579,950,182  |  |

<sup>+</sup> See chapter 19 for defined terms.

| Step 2: Calculate 15% of "A"   |   |  |
|--|---|--|
| "B"  | 0.15<br>[Note: this value cannot be changed]  |  |
| <i>Multiply</i> "A" by 0.15  | 86,992,527  |  |
| Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used  |   |  |
| <ul> <li>Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> | 500,000 – 19 December 2016<br>3,000,000 – 27 February 2017<br>600,000 – 20 June 2017<br>350,000 - 7 September 2017<br>75,000 – 13 November 2017 |  |
| "C"  | 4,525,000   |  |
| Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1   |   |  |
| "A" x 0.15<br>Note: number must be same as shown in<br>Step 2  | 86,992,527  |  |
| <i>Subtract</i> "C"<br>Note: number must be same as shown in<br>Step 3   | 4,525,000   |  |
| <i>Total</i> ["A" x 0.15] – "C"  | <b>82,467,527</b><br>[Note: this is the remaining placement<br>capacity under rule 7.1]   |  |

<sup>+</sup> See chapter 19 for defined terms.

# Part 2

| Rule 7.1A – Additional placement capacity for eligible entities<br>Step 1: Calculate "A", the base figure from which the placement<br>capacity is calculated   |  |  |
|--|--|--|
|  |  |  |
| Step 1 of Part 1 Step 2: Calculate 10% of "A"  |  |  |
| "D"  | 0.10<br>Note: this value cannot be changed |  |
| <i>Multiply</i> "A" by 0.10  | -  |  |
| Step 3: Calculate "E", the amount of placement capacity under rule<br>7.1A that has already been used  |  |  |
| <i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A  | -  |  |
| <ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> |  |  |
|  |  |  |

<sup>+</sup> See chapter 19 for defined terms.

| Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A |  |  |
|---|--|--|
| "A" x 0.10<br>Note: number must be same as shown in<br>Step 2                                   | -  |  |
| <i>Subtract</i> "E"<br><i>Note: number must be same as shown in</i><br><i>Step 3</i>            | -  |  |
| <i>Total</i> ["A" x 0.10] – "E"   | -<br>Note: this is the remaining placement<br>capacity under rule 7.1A |  |

<sup>+</sup> See chapter 19 for defined terms.